Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bullboard Posts
Comment by Lykitison Jun 18, 2014 2:29pm
168 Views
Post# 22672158

RE:RE:RE:NEW PRESENTATION ON WEBSITE!

RE:RE:RE:NEW PRESENTATION ON WEBSITE!Solidly build presentation. Very impressive. Speaks to both scientific/pharmaceutical community and the layman.
I note -many things- but this in particular: specific language around what is "currently" going on vs. what may have already occurred...

(slide 3): Several drug development programs are currently
underway

(slide 45): Several drug development programs are
underway with leading drug companies
•  Neurodegenera-ve Diseases (Alzheimer’s)
•  Metabolic Diseases (Lysosomal Storage Diseases)
•  Oncology (Metasta-c Breast Cancer)

(slide 45): Four strategic collaborations are underway or
have been completed with world-leading
pharmaceu-cal companies inves-gated the
use of the Transcend Family with their target
therapeu-c compounds
 

Bullboard Posts